Clinical Trial Update: Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating fractionated gemtuzumab ozogamicin for patients with measurable residual disease in acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: University of Washington | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING